射血分数降低心衰的药物治疗:CHAMP-HF注册研究
CHAMP-HF注册研究纳入美国150家诊所的3518例慢性HFrEF门诊患者,评估指南推荐药物使用与剂量。结果显示ACEI/ARB/ARNI、β受体阻滞剂和MRA未处方比例分别为27%、33%和67%,且达到目标剂量者比例低,仅1%患者同时达到三类药物目标剂量。
要点
- 门诊HFrEF患者中指南推荐药物使用和剂量存在显著缺口。
- MRA未处方率最高(67%),但处方者中77%达到目标剂量。
- 仅1%符合条件的患者同时达到ACEI/ARB/ARNI、β受体阻滞剂和MRA的目标剂量。
核心结论
- 当代门诊HFrEF注册研究中,指南导向药物治疗的使用和剂量仍存在显著缺口。
研究设计与样本
- CHAMP-HF注册研究为美国多中心门诊注册,纳入150家初级保健和心内科诊所的3518例慢性HFrEF患者,平均年龄66±13岁,女性占29%,平均EF 29±8%。
主要发现
- 符合条件患者中,27%未处方ACEI/ARB/ARNI,33%未处方β受体阻滞剂,67%未处方MRA。
- 处方患者中,达到目标剂量的比例分别为ACEI/ARB 17%、ARNI 14%、β受体阻滞剂28%、MRA 77%。
- 符合所有类别药物的患者中,仅1%同时达到ACEI/ARB/ARNI、β受体阻滞剂和MRA的目标剂量。
- 调整模型中,年龄较大、血压较低、功能分级更差、肾功能不全和近期心衰住院通常与较低的药物使用或剂量相关。
- 社会经济特征与药物使用或剂量无独立关联。
临床怎么用
- 门诊应系统评估HFrEF患者指南推荐药物的使用与剂量,尤其关注MRA的启用。
- 对高龄、低血压、肾功能不全等高危因素患者,仍需在耐受前提下努力优化剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines strongly recommend patients with heart failure with reduced ejection fraction (HFrEF) be treated with multiple medications proven to improve clinical outcomes, as tolerated. The degree to which gaps in medication use and dosing persist in contemporary outpatient practice is unclear. OBJECTIVES: This study sought to characterize patterns and factors associated with use and dose of HFrEF medications in current practice. METHODS: The CHAMP-HF (Change the Management of Patients with Heart Failure) registry included outpatients in the United States with chronic HFrEF receiving at least 1 oral medication for management of HF. Patients were characterized by baseline use and dose of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin receptor neprilysin inhibitor (ARNI), beta-blocker, and mineralocorticoid receptor antagonist (MRA). Patient-level factors associated with medication use were examined. RESULTS: Overall, 3,518 patients from 150 primary care and cardiology practices were included. Mean age was 66 ± 13 years, 29% were female, and mean EF was 29 ± 8%. Among eligible patients, 27%, 33%, and 67% were not prescribed ACEI/ARB/ARNI, beta-blocker, and MRA therapy, respectively. When medications were prescribed, few patients were receiving target doses of ACEI/ARB (17%), ARNI (14%), and beta-blocker (28%), whereas most patients were receiving target doses of MRA therapy (77%). Among patients eligible for all classes of medication, 1% were simultaneously receiving target doses of ACE/ARB/ARNI, beta-blocker, and MRA. In adjusted models, older age, lower blood pressure, more severe functional class, renal insufficiency, and recent HF hospitalization generally favored lower medication utilization or dose. Social and economic characteristics were not independently associated with medication use or dose. CONCLUSIONS: In this contemporary outpatient HFrEF registry, significant gaps in use and dose of guideline-directed medical therapy remain. Multiple clinical factors were associated with medication use and dose prescribed. Strategies to improve guideline-directed use of HFrEF medications remain urgently needed, and these findings may inform targeted approaches to optimize outpatient medical therapy.
引用
- Greene SJ, Butler J, Albert NM, et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018. PMID: 30025570. doi:10.1016/j.jacc.2018.04.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。